Latest important developments
Substantive changes, not a count of publications or repeated press coverage.
No records match these filters.
Preclinical
Blocking fibronectin restored remyelination in experimental models
A PNAS study found that loss of endothelial TNFR2 causes fibronectin to accumulate in demyelinated lesions, trapping OPCs and obstructing repair. Systemic fibronectin inhibition restored myelination and clinical remission in EAE and cuprizone models.
What this means clinicallyThis is a strong new mechanistic target, but there is no human trial or approved medicine for this approach yet.
Source quality: High for a preclinical finding • peer-reviewed primary paper
Translational
Low-dose theophylline patch receives funding for GMP development and Phase 1 preparation
Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to move a low-dose transdermal theophylline patch toward industrial and GMP production and a planned Phase 1 study in healthy volunteers. The approach targets HDAC2 and has a preclinical rationale for myelin repair.
What this means clinicallyThe funding narrows the translational gap, but Phase 1 is not yet publicly registered and there are no efficacy data in people with MS.
Source quality: Official university update plus peer-reviewed formulation work
Phase 3 platform
OCTOPUS: the first interim metformin/ALA analysis is scheduled for September 2026
The OCTOPUS Stage 1 analysis in progressive MS will assess metformin and alpha-lipoic acid. In addition to brain-atrophy MRI, the plan now includes EDSS, Timed 25-Foot Walk and 9-Hole Peg Test measures.
What this means clinicallyThis is one of the nearest important milestones in progressive MS. Stage 1 may decide which arm continues, but it is not a final Phase 3 result.
Source quality: High for trial status • official academic update
Phase 2 • planned
Lucid-MS: FDA lifts the clinical hold, allowing a planned Phase 2 to move forward
After an earlier clinical hold, the FDA allowed the Lucid-MS IND to proceed. The company plans a randomised, double-blind, placebo-controlled Phase 2 in progressive MS for the PAD2 inhibitor Lucid-21-302.
What this means clinicallyThis is permission to begin clinical development, not evidence that the drug remyelinates or improves outcomes. As of 16 September 2026, no public Phase 2 registration or recruiting site had been located.
Source quality: Official company SEC filing • not a peer-reviewed efficacy result
Preclinical
CN045 promoted human OPC differentiation and remyelination in mice
An npj Drug Discovery paper described CN045, a CNS-penetrant lead that promoted OPC differentiation and myelin-like ensheathment in human cells in vitro and increased remyelination in a mouse demyelination model.
What this means clinicallyThis is an interesting drug-development lead, but it remains preclinical. Pharmacokinetic optimisation, toxicology and then human testing are still required.
Source quality: High for a preclinical finding • peer-reviewed primary paper
Phase 1
PTD802: FDA clearance for the first human study
The FDA cleared the IND for PTD802, an oral selective GPR17 antagonist designed to release a brake on OPC maturation and promote remyelination.
What this means clinicallyThis is an important step from laboratory work to human testing, but no efficacy data in people with MS are available yet.
Source quality: Official company regulatory announcement • no efficacy data yet
Preclinical
Rutgers advances new mGluR5 agonists for preclinical myelin-repair development
Rutgers presented a series of more potent small-molecule mGluR5 agonists that promote myelin-protein production in human oligodendrocytes and have shown activity in animal models.
What this means clinicallyThis is an early translational programme available for licensing or collaboration, not a clinical trial. Lead selection and optimisation are needed before human testing.
Source quality: Official university technology-transfer source • not clinical evidence
Phase 3
RESTORE: Phase 3 clemastine study terminated after a futility no-go analysis
RESTORE, which tested clemastine in people with MS and internuclear ophthalmoparesis, was terminated. The registry says slow recruitment led to a futility analysis with a no-go outcome.
What this means clinicallyThis is an important negative development for this study, but it should not be presented as a clean efficacy result: the decision followed a futility analysis in a trial with serious recruitment difficulty.
Source quality: High • ClinicalTrials.gov registry status
Phase 2
ReWRAP: bazedoxifene missed remyelination endpoints in Phase 2
In ReWRAP, bazedoxifene was generally well tolerated but did not produce a statistically significant improvement in the primary MRI myelin-water-fraction endpoint or secondary efficacy endpoints.
What this means clinicallyAnother agent with strong preclinical evidence did not translate its remyelination signal into a positive human Phase 2 result.
Source quality: High • completed trial registry plus ACTRIMS presentation
Preclinical
Bavisant / BRAVEinMS shows a strong multi-model preclinical remyelination and neuroprotection signal
After screening more than 1,500 repurposable compounds, bavisant, a histamine H3-receptor antagonist, showed remyelination and neuroprotection across several models, including human oligodendroglial assays and a humanised chimeric mouse model.
What this means clinicallyThis is one of the stronger new repurposing leads, but it remains preclinical. There is no registered trial in people with MS and no demonstrated clinical benefit.
Source quality: High for a preclinical finding • Science Translational Medicine
Preclinical
DITPA / Petratos: new preclinical readout reports neuroprotection and myelin repair in EAE
Steven Petratos's team reported that daily oral DITPA limited neurological deterioration, increased oligodendrocyte survival, reduced myelin and axonal injury and improved remyelination markers in EAE.
What this means clinicallyThis is a serious translational programme with active preclinical development, but no publicly registered MS clinical trial. Mouse results are not evidence of clinical benefit.
Source quality: Preliminary • preprint, peer review not completed
Phase 2
PIPE-307: Phase 2 VISTA missed its efficacy endpoints
In relapsing-remitting MS, VISTA reported acceptable safety and tolerability, but PIPE-307 did not meet its prespecified primary or secondary efficacy endpoints.
What this means clinicallyOne of the most discussed remyelination-specific compounds did not demonstrate clinical efficacy in Phase 2; further MS development remains uncertain.
Source quality: High for topline status • official SEC filing, not a peer-reviewed full paper
Phase 2a
CCMR Two: positive biological remyelination signal with metformin plus clemastine
Twenty-four weeks of metformin plus clemastine significantly reduced visual-evoked-potential latency, a finding consistent with remyelination. Visual function and disability did not improve over the study's short duration.
What this means clinicallyThis is one of the stronger human proof-of-concept signals, but not evidence that the treatment improves symptoms or reverses disability.
Source quality: Moderate to high • official academic headline results; full peer-reviewed publication pending